Insider Trading March 14, 2026

SI-BONE Director Disposes of 4,100 Shares as Stock Trades Near 52-Week Low

Mika Nishimura reduces stake following a March 12 sale; company posts stronger-than-expected Q4 2025 results and sees analyst price-target revisions

By Derek Hwang SIBN
SI-BONE Director Disposes of 4,100 Shares as Stock Trades Near 52-Week Low
SIBN

SI-BONE, Inc. director Mika Nishimura sold 4,100 shares on March 12, 2026 for roughly $56,700, according to a Form 4 filing. The sale occurred as the stock hovered near its 52-week low and after the company reported better-than-expected Q4 2025 results that prompted an upward price-target adjustment from Truist Securities.

Key Points

  • Director Mika Nishimura sold 4,100 SI-BONE shares on March 12, 2026 at $13.82 to $13.86 per share; the Form 4 was signed March 13, 2026 by Michael Pisetsky.
  • After the sale, Nishimura directly owns 32,716 shares, which include 8,675 shares issuable upon settlement of restricted stock units.
  • SI-BONE's Q4 2025 results beat consensus - EPS of -$0.04 vs -$0.12 and revenue of $56.3 million vs $54.7 million; Truist raised its price target to $24 and analysts' targets range from $22 to $32.

SI-BONE, Inc. (NASDAQ:SIBN) reported a director-level sale in mid-March when Mika Nishimura divested 4,100 common shares for about $56,700. The transactions took place on March 12, 2026, at prices between $13.82 and $13.86 per share, and the related Form 4 filing with the Securities and Exchange Commission was signed on March 13, 2026 by Michael Pisetsky, acting as Attorney-in-Fact for Ms. Nishimura.

Following the disposition, Nishimura's direct holdings in SI-BONE stand at 32,716 shares. That total includes 8,675 shares that are issuable upon settlement of restricted stock units.

The sale comes while the shares are trading close to their 52-week low of $12.49 and amid a year-to-date decline of approximately 34%.


Recent financials and analyst reaction

SI-BONE reported fourth-quarter 2025 results that outperformed consensus projections. The company posted earnings per share of -$0.04, compared with a forecasted -$0.12. Revenue for the quarter was $56.3 million versus an expected $54.7 million. Management also reported positive cash flow and a gross margin improvement, while adjusted EBITDA came in roughly $3 million above consensus estimates.

Market analysts have reacted to these results. Truist Securities raised its price target for SI-BONE to $24 from $23 and maintained a Buy rating on the stock. Broader analyst coverage reflected price targets in a range from $22 to $32, indicating continued bullishness among some sell-side firms.

Market-value metrics cited in available research put SI-BONE's market capitalization at approximately $576 million. InvestingPro analysis, as noted in company research summaries, characterized the stock as slightly undervalued and points to additional proprietary Pro Research materials for deeper valuation context.


Context and documentation

The insider sale was documented via a Form 4 filed with the SEC and executed by Michael Pisetsky on March 13, 2026 on behalf of Mika Nishimura. No additional insider transactions or changes to Nishimura's holdings beyond the amounts and figures cited above were reported in that filing.

This report presents the transaction details, recent company results and the resulting analyst adjustments without speculation on future share performance.

Risks

  • Share-price volatility - the stock was trading near its 52-week low of $12.49 and is down about 34% year-to-date, reflecting market risk for equity holders in the medical device sector.
  • Insider sales - director-level disposals may influence investor perception and could affect short-term market sentiment for SI-BONE shares.
  • Execution and margin risks - while Q4 2025 results exceeded expectations with positive cash flow and adjusted EBITDA ahead of consensus, future quarter-to-quarter performance and margin sustainability remain uncertain.

More from Insider Trading

Equinix Executive Vice President Sells $563,961 of Stock Following RSU Vesting Mar 14, 2026 Guidewire CFO Sells $755K in Stock Amid Mixed Analyst Views and Strong ARR Growth Mar 14, 2026 Equinix legal chief executes stock sale after RSU exercise as company advances debt and acquisition moves Mar 14, 2026 Pegasystems Product Chief Sells Shares After Exercising Options; Analyst Views Diverge Mar 14, 2026 eBay Growth Chief Disposes $1.36M in Shares as Company Posts Solid Quarter and Strategic Moves Mar 14, 2026